Literature DB >> 26310908

Strategies for combining immunotherapy with radiation for anticancer therapy.

Steven N Seyedin1, Jonathan E Schoenhals2, Dean A Lee3, Maria A Cortez2, Xiaohong Wang2, Sharareh Niknam2, Chad Tang1, David S Hong4, Aung Naing4, Padmanee Sharma5, James P Allison5, Joe Y Chang1, Daniel R Gomez1, John V Heymach6, Ritsuko U Komaki1, Laurence J Cooper7, James W Welsh1.   

Abstract

Radiation therapy controls local disease but also prompts the release of tumor-associated antigens and stress-related danger signals that primes T cells to promote tumor regression at unirradiated sites known as the abscopal effect. This may be enhanced by blocking inhibitory immune signals that modulate immune activity through a variety of mechanisms. Indeed, abscopal responses have occurred in patients with lung cancer or melanoma when given anti-CTLA4 antibody and radiation. Other approaches involve expanding and reinfusing T or NK cells or engineered T cells to express receptors that target specific tumor peptides. These approaches may be useful for immunocompromised patients receiving radiation. Preclinical and clinical studies are testing both immune checkpoint-based strategies and adoptive immunotherapies with radiation.

Entities:  

Keywords:  CAR T cells; OX40; abscopal effect; immune checkpoints; immunotherapy; ipilimumab; lung cancer; melanoma; nivolumab; radiation

Mesh:

Substances:

Year:  2015        PMID: 26310908      PMCID: PMC4825325          DOI: 10.2217/imt.15.65

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  102 in total

1.  OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.

Authors:  Takanori So; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

2.  Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue.

Authors:  Silvia Piconese; Eleonora Timperi; Ilenia Pacella; Valeria Schinzari; Claudio Tripodo; Massimo Rossi; Nicola Guglielmo; Gianluca Mennini; Gian Luca Grazi; Simona Di Filippo; Stefania Brozzetti; Katia Fazzi; Guido Antonelli; Maria Antonietta Lozzi; Massimo Sanchez; Vincenzo Barnaba
Journal:  Hepatology       Date:  2014-06-26       Impact factor: 17.425

Review 3.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

4.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

5.  Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer.

Authors:  Dejan Baskic; Lazar Vujanovic; Nebojsa Arsenijevic; Theresa L Whiteside; Eugene N Myers; Nikola L Vujanovic
Journal:  Head Neck       Date:  2012-04-05       Impact factor: 3.147

6.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

7.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Authors:  S F Slovin; C S Higano; O Hamid; S Tejwani; A Harzstark; J J Alumkal; H I Scher; K Chin; P Gagnier; M B McHenry; T M Beer
Journal:  Ann Oncol       Date:  2013-03-27       Impact factor: 32.976

Review 8.  Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).

Authors:  Amanda K Purdy; Kerry S Campbell
Journal:  Cancer Biol Ther       Date:  2009-12-28       Impact factor: 4.742

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

Authors:  Minghui Li; Aaron R Bolduc; Md Nasrul Hoda; Denise N Gamble; Sarah-Bianca Dolisca; Anna K Bolduc; Kelly Hoang; Claire Ashley; David McCall; Amyn M Rojiani; Bernard L Maria; Olivier Rixe; Tobey J MacDonald; Peter S Heeger; Andrew L Mellor; David H Munn; Theodore S Johnson
Journal:  J Immunother Cancer       Date:  2014-07-07       Impact factor: 13.751

View more
  28 in total

1.  An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report.

Authors:  Alexander D Sherry; Michael Bezzerides; Mohamed H Khattab; Guozhen Luo; Kristin K Ancell; Austin N Kirschner
Journal:  Strahlenther Onkol       Date:  2020-01-31       Impact factor: 3.621

2.  Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.

Authors:  Iris Fried; Alex Lossos; Tal Ben Ami; Rina Dvir; Helen Toledano; Myriam Weil Ben Arush; Sergei Postovski; Abed Abu Kuidar; Michal Yalon; Michael Weintraub; Mony Benifla
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

Review 3.  Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes.

Authors:  Kalpana Mujoo; Clayton R Hunt; Raj K Pandita; Mauro Ferrari; Sunil Krishnan; John P Cooke; Stephen Hahn; Tej K Pandita
Journal:  Mol Cancer Res       Date:  2018-03-28       Impact factor: 5.852

Review 4.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

Review 5.  Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.

Authors:  Jonathan E Schoenhals; Steven N Seyedin; Clark Anderson; Eric D Brooks; Yun R Li; Ahmed I Younes; Sharareh Niknam; Ailin Li; Hampartsoum B Barsoumian; Maria Angelica Cortez; James W Welsh
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 6.  Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).

Authors:  James P Flynn; Mark H O'Hara; Saumil J Gandhi
Journal:  Transl Lung Cancer Res       Date:  2017-04

7.  Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Authors:  Sharareh Niknam; Hampartsoum B Barsoumian; Jonathan E Schoenhals; Heather L Jackson; Niranjan Yanamandra; Mauricio S Caetano; Ailin Li; Ahmed I Younes; Alexandra Cadena; Taylor R Cushman; Joe Y Chang; Quynh N Nguyen; Daniel R Gomez; Adi Diab; John V Heymach; Patrick Hwu; Maria Angelica Cortez; James W Welsh
Journal:  Clin Cancer Res       Date:  2018-05-21       Impact factor: 12.531

Review 8.  Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis.

Authors:  Jean-Pierre Pouget; Alexandros G Georgakilas; Jean-Luc Ravanat
Journal:  Antioxid Redox Signal       Date:  2018-03-22       Impact factor: 8.401

9.  Challenges in the delivery of therapies to melanoma brain metastases.

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Brynna-Wilken Resman; Karen E Parrish; Svetomir N Markovic; Jann N Sarkaria; William F Elmquist
Journal:  Curr Pharmacol Rep       Date:  2016-11-09

10.  Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.

Authors:  Dean A Lee; Cecele J Denman; Gabriela Rondon; Glenda Woodworth; Julianne Chen; Tobi Fisher; Indreshpal Kaur; Marcelo Fernandez-Vina; Kai Cao; Stefan Ciurea; Elizabeth J Shpall; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.